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drugs and combinations of therapy including lung cancer cell lines, 
xenografts, including orthotopic (lung) xenografts and xenografts made 
directly from patient samples without intervening cell culture. For this 
reason we have developed a very large (>200) panel of lung cancer cell 
lines of all histologic types and including all of the various genetic 
changes found in lung cancer. Coupled with this we have developed 
xenograft models (including orthotopic models) of lung cancer in >50 
lung cancers including xenografts made from lung cancer lines and 
from primary patient materials. We can determine expression proﬁles in 
these preclinical models as a step toward developing biomarker 
signatures that can be tested in the clinic. The use of bioluminescence 
imaging (BLI) to help follow the growth and response of xenografts to 
therapy is an important new tool. From all of these we need to know 
how good or bad such preclinical model systems are in both identifying 
drug response phenotypes and in developing predictive signatures that 
will work in patient specimens. For example the whole EGFR TKI 
story coupled with EGFR TK domain mutations as well as EGFR TKI 
resistance was present in the large panel of lung cancer cell lines and 
xenografts we have developed. Because of this we have been testing 
several new drugs in development alone and in combination such as a 
SMAC mimetic and Peloruside A. We have found not only dramatic 
differences between lung cancer cells in response to the drugs as single 
agents, but complex patterns of synergy (which are often dramatic) 
when they are combined with standard drugs. Genome Wide Ap-
proaches to Discovery of New Therapeutic Targets Including 
Synthetic Lethal Screens Large scale DNA sequencing and DNA 
ampliﬁcation screens are going on to ﬁnd oncogenic changes that repre-
sent “druggable” targets. However, another approach that is gaining 
attention are genome wise functional screens for such targets such as 
genome wide screening of siRNA and shRNA libraries for genes that 
when knocked down sensitize tumor cells to low doses of chemothera-
py agents. This approach has led to the discovery of 87 genes, which 
when knocked down by siRNAs dramatically sensitize lung cancer 
cells to paclitaxel. This information could provide “signatures” for 
predicting paclitaxel response, but also targets that could be addressed 
in combination with paclitaxel. Some of these (such as a panel of 
cancer testis antigen genes) are selectively expressed in tumor cells. Of 
course these siRNA/shRNA screens can be coupled with screening of 
small molecule libraries. Related to this is miRNA proﬁling which 
identiﬁed two miRNAs whose expression was inversely correlated with 
paclitaxel resistance. By re expressing these two miRNAs, paclitaxel 
resistant lung cancers were converted to a paclitaxel sensitive pheno-
type. Thus, such miRNAs can be considered for therapeutic develop-
ment. Lung Cancer Stem Cells There is considerable evidence 
mounting that a small subset of lung cancer cells (~1% or less of the 
total tumor cell population) has the properties consistent to give immor-
tal and metastatic disease and are referred to as “cancer stem cells” or 
“stem-like” cells. We have developed ways to isolate and study these 
cells and they have clear differences in gene expression programs for a 
variety of stem cell proliferation genes as well as increased ability to 
clone in soft agar, form tumors in xenografts, and give metastatic 
disease in xenografts. Key issues will be to develop good, easy to use 
markers (such as monoclonal antibodies) to identify these cells, to see 
how their response to therapy compares with the bulk of the tumor 
(since it is likely they may be more resistant to therapy), and whether 
their presence or amount is of prognostic signiﬁcance. Of course their 
identiﬁcation in preneoplastic stages will be important as new molecu-
lar markers for early lung cancer detection. New Model Systems for 
Studying Lung Cancer Pathogenesis In order to determine which 
steps are most important we have developed a new system for 
immortalizing human bronchial epithelial cells (HBECs) in the absence 
of viral oncoproteins using hTERT (human telomerase providing part 
of the immortalization pathway) and cdk4 (bypassing the p16/Rb 
checkpoint) expression vectors. We have established over 30 such 
strains from persons with and without lung cancer. These expressed 
stem cell markers, can differentiate in 3 dimensional cultures into 
ciliated epithelium and are do not expression malignant properties. We 
have added oncogenic KRAS (found in 30% of non-small cell lung 
cancers, NSCLC) and knocked out p53 (found in 50% of all lung 
cancers) alone or together. These (together with hTERT and cdk4) only 
partially progress the HBECs toward malignancy. We have also made 
changes in multiple other genes such as CMYC, BCL2, PTEN, and 
EGFR and ﬁnd that again these only partially progress HBECs towards 
malignancy. However, combining KRASV12, p53 knockdown, and 
CMYC coupled with biologic selection in SCID mice can identify a 
subset of fully malignant tumor cells. IN addition, the addition of these 
oncogenic changes leads to changes in cytokine secretion patterns that 
provide new information for early lung cancer detection through 
screening for these cytokines in blood. These HBECs are providing a 
new model for systematically testing the importance of additional 
genetic changes in lung cancer pathogenesis. In developments by 
several other groups, mouse models of lung cancer have been devel-
oped based on genetic abnormalities found in human lung cancer with 
development of mouse systems for speciﬁc development of these 
abnormalities in lung as a target tissue. These have been developed for 
non-small cell lung cancer (NSCLC) (based on oncogenic KRAS) and 
for small cell lung cancer (SCLC) (based on p53 and Rb abnormali-
ties). These models are proving extremely valuable in the preclinical 
testing of early detection, chemoprevention, and new treatment 
strategies. 
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The pulmonary environment presents a unique milieu in which lung 
carcinogenesis proceeds in complicity with the host cellular network. 
The pulmonary diseases that are associated with the greatest risk for 
lung cancer are characterized by abundant and deregulated inﬂam-
mation. Pulmonary disorders such as chronic obstructive pulmonary 
disease (COPD)/emphysema and pulmonary ﬁbrosis are characterized 
by profound abnormalities in inﬂammatory-ﬁbrotic pathways. For 
example, among the cytokines and growth factors aberrantly produced 
in these lung diseases and the developing tumor microenvironment 
(TME), IL-1β, PGE2, and TGF-β have been found to have deleteri-
ous properties that simultaneously pave the way for both epithelial 
mesenchymal transition (EMT) as well as destruction of speciﬁc host 
cell-mediated immune responses. Loss of E-cadherin expression by 
epithelial cells is a characteristic of EMT and is associated with pro-
gression of lung cancer. Our recent work and that of others implicates 
E-cadherin expression as a marker of sensitivity to epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKI) in NSCLC. 
In fact a biological signature that would allow for the detection of 
EGFR TKI-sensitive NSCLC tumor cells with an activated EGFR 
pathway has recently been identiﬁed, independent from the mecha-
nism leading to activation. A gene signature indicative of an epithelial 
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versus mesenchymal phenotype appears to be predictive of EGFR TKI 
-mediated growth inhibition in NSCLC tumor cell lines. These ﬁndings 
also suggest that EMT features may serve as potential biomarkers in 
predicting EGFR TKI clinical activity in NSCLC patients. Our recent 
studies have shown that inﬂammatory mediators are potent regulators 
of E-cadherin expression in lung cancer: IL-1β and PGE2 contribute 
to the downregulation of E-cadherin expression in NSCLC via distinct 
pathways that include induction of the transcriptional repressors ZEB-
1, Snail1 and Twist, and the PGE2 pathway upregulates the E-cadherin 
ubiquitin ligase, Hakai. Here we report on new studies that deﬁne the 
cellular elements within the TME that contribute these inﬂammatory 
mediators affecting expression and maintenance of E-cadherin, as 
well as other markers of EMT. These relationships are being assessed 
in organotypic model systems. Thus, TME-mediated inﬂammation 
provides a pathway to both EMT and resistance to targeted therapies in 
NSCLC. Full deﬁnition of these pathways will afford the opportunity to 
intervene in speciﬁc inﬂammatory events mediating lung tumorigenesis 
and resistance to therapy.
Supported by the UCLA SPORE in Lung Cancer (NCI P50 CA90388) 
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In the post-genome era mouse is becoming an increasingly important 
tool of lung cancer research. The application of innovative technologies 
to generate accurate mouse models is likely to accelerate the discovery 
of new molecular targets and imaging biomarkers for the early detec-
tion of lung cancer (1,2). It remains to be seen which models will be 
most suitable for preclinical tests (3).
Comparative oncology of lung tumors
While mice and humans share many similarities in the molecular pa-
thology of lung tumorigenesis, there are also differences. Much of the 
earlier work focused on chemical carcinogenesis establishing parallel 
roles of many toxic chemicals as well as genetic and epigenetic altera-
tions in lung carcinogenesis of mice and humans (4). The incidence 
of spontaneous (and induced) lung tumors among the commonly used 
inbred strains varies markedly from high 61% in A/J mice to very 
low 6 % in C57Bl6 for males at 2 years. Unlike humans with four 
distinct lung cancer types that readily disseminate and reveal complex 
molecular genetics, mice are prone to pulmonary adenomas which are 
rare in humans or, infrequently, to adenocarcinomas, which seldom 
metastasize. Both of these mouse tumors are predominantly associated 
with Kras mutations. Premalignat lesions that are well characterized in 
the human airway epithelium and squamous cell carcinoma have been 
surprisingly difﬁcult to replicate in mice.
Does smoking cause lung cancer in mice? 
For decades, the credibility of mouse models suffered because of the 
lack of evidence that tobacco smoke, the main cause of lung cancers in 
humans, would lead to lung tumors in mice. Finally, lung tumors were 
induced reproducibly in A/J mice by exposing them to cigarette smoke 
for 5 months followed by a critically important 4 month recovery 
period (5). In a recent study, exposure of strain B6C3F1 female mice to 
life-time cigarette smoke (30 months) lead to 48% incidence of benign 
and malignant lung tumors through distinct genetic and epigenetic 
pathways (6). In comparison, 9.5% of control animals got tumors.
In contrast, cigarette smoke carcinogens such as the tobacco-speciﬁc 
nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) 
and benzo[a]pyrene (B[a]P) readily cause lung tumors in mice and have 
been widely used in studies on pathogenesis, chemoprevention and 
novel therapies (4).
Directing gene expression and cancer to lung
The development of methods for manipulating the mouse genome, 
combined with the sequencing of the mouse genome, has advanced 
our ability to develop a plethora of new, genetically engineered mouse 
(GEM) models for lung cancer. In many cases the genetic modiﬁcations 
are targeted to speciﬁc subsets of lung epithelial cells. The surfactant 
protein-C promoter directs the expression mainly into alveolar type II 
cells in the parenchyma, while CC10/CCSP promoters primarily target 
the nonciliated secretory (Clara) cells along the airways. The ﬁrst GEM 
lung cancer models involved the constitutive expression of SV40 Tag 
using these promoters, which resulted in aggressive adenocarcinomas 
without metastases (2). Many other transgenic mice followed using the 
same strategy, providing good models for observed ampliﬁcation and 
epigenetic modiﬁcation of the oncogenes. Same promoters are also 
used in many conditional mouse models. 
Conditional bitransgenic mouse models for lung adenocarcinoma, 
oncogene dependency and stem cells
Most oncogenic activating mutations in lung cancer are somatic, which 
prompted the generation of conditional models, where activation of ge-
netic events can be regulated both temporally and spatially (1). Muta-
tions in Ras oncogenes are commonly associated with both human and 
mouse adenocarcinomas. A tetracycline inducible K-Ras4G12D lung 
tumor model developed epithelial cell hyperplasia, adenomas and ad-
enocarcinomas after administration of doxycyclin. Interestingly, tumors 
completely regressed after withdrawal of doxycyclin demonstrating on-
cogene dependency. In a sporadic tumor model using Cre/loxP system a 
mutation can be directed to occur strictly in a set of differentiated cells 
while the genome of the adjacent cells remains unaltered. As a proof of 
principle, adeno-Cre-mediated expression of mutant alleles of oncogen-
ic K-RasG12D or K-RasG12V in the lung produced multiple adenomas 
and adenocarcinomas, revealing the precise role of Ras oncogenes in 
human lung carcinogenesis. Same approach helped to identify potential 
stem cells, BASCs in the peripheral lung.
Model for Small Cell Lung Cancer (SCLC) 
Almost all human SCLCs have sustained mutations of p53 and Rb1 
which rarely occur in mice. Somatic application of the Cre-loxP system 
was used to obtain primarily airway epithelium speciﬁc deletion of 
Rb1 and p53, which resulted in multiple tumors closely resembling 
human SCLCs (2). It is notable that the tumors demonstrated neuro-
endocrine features and had a marked capacity to metastasize to liver, 
brain, adrenal gland, bone and ovaries which mirrors the behavior of 
human SCLCs. Cell lines obtained from the mouse tumors also re-
vealed characteristics of SCLC including ampliﬁcation of L-myc. Other 
lung cancer models such as CC10-SV40 Tag/hASH1 bitransgenic or 
p18/Men1 deﬁcient mice have also been associated with pulmonary 
neuroendocrine tumors, but lack the typical histology and metastatic 
pattern of SCLC (7,8) 
Squamous cell carcinogenesis in mouse lung
Normally neither human nor mouse lung contains squamous epithe-
lium. However, the classic sequence of premalignant changes in human 
